Altman Clinical and Translational Research Institute
La Jolla, California, 92093, United States
Location status: Recruiting
NCT Number: NCT07189234
In a randomized controlled trial, the investigators intend to measure the health impact of time restricted eating (TRE) in patients with metabolic syndrome (with elevated blood pressure and at least 2 of the following: increased waist circumference, abnormal cholesterol levels, elevated triglycerides, and elevated fasting glucose levels), who habitually eat more than 12 hours every day. Patients will be randomly assigned to a control group (standard of care) or intervention group (TRE).
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Phase 2
La Jolla, California, 92093, United States
Location status: Recruiting
Circadian rhythms optimize nutrient homeostasis by orchestrating catabolic and anabolic metabolism to appropriate times of the 24 hour day. Chronic circadian rhythm disruption predisposes individuals to metabolic diseases including obesity and type 2 diabetes. Conversely, maintaining a daily rhythm of feeding and fasting cycles sustains a robust circadian rhythm which improves cellular bioenergetics and results in improved metabolism. Time-restricted eating (TRE) is a specific feeding-fasting pattern in which feeding is restricted to 8-12 hours a day.
Over the 54-week duration of the study, participants will be required to use a smartphone application (myCircadianClock, developed by the Salk Institute) to log all food and beverage intake. Investigators will measure height, weight, waist circumference, and blood pressure throughout the study. Blood tests will be done after an overnight fast to check HbA1C, glucose, insulin, lipids, and an NMR lipoprotein profile. Blood sugar will also be monitored continuously using a continuous glucose monitor (CGM) worn for 2 weeks at the beginning of the study, at 6 months, and at 12 months (end of the study). At these same three timepoints, participants will also wear a wrist-worn actigraphy device (actiwatch) to track physical activity and sleep patterns. Body composition will be measured using a dual energy X-ray absorptiometry (DEXA) scan, and an oral glucose tolerance test (OGTT) will be performed to assess how the body responds to sugar.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants in this arm will adhere to a daily, consistent 10-hour eating window for the course of the study as well as receive nutritional counseling from the study dietician.
Participants in this arm will receive nutritional counseling from the study dietician, but will not be required to adopt the 10-hour eating window.
Time frame: 54 weeks
Assessed via HbA1c (%)
Time frame: 54 weeks
Measured by continuous glucose monitor (CGM)
Time frame: 54 weeks
LDL cholesterol (mg/dl)
Time frame: 54 weeks
Bone density measured by DEXA scan (g/cm^2)
Time frame: 54 weeks
Measured by oral glucose tolerance test (OGTT)
Time frame: 54 weeks
Muscle mass measured by DEXA scan (kg)
Time frame: 54 weeks
Measured by body fat percentage via DEXA scan (%)
Contact information is provided by the study sponsor or research team.
University of California, San Diego
Other
TIMET 2.0 - Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health
Acronym: TIMET 2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04057339
Behavior, Fasting
La Jolla, California, United States
View Trial DetailsNCT05654142
Body Weight, CARDIOMETABOLIC CONDITIONS
Chicago, Illinois, United States
View Trial DetailsNCT05121844
Body Weight, Body Weight Changes
Palo Alto, California, United States
View Trial DetailsNCT05114018
Body Weight, Glucose Intolerance
Kiel, Germany
View Trial Details